These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9412619)

  • 61. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.
    Song HY; Son KB; Shin JY; Bae S
    Int J Clin Pharm; 2019 Dec; 41(6):1434-1441. PubMed ID: 31522377
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Singer DE; Albers GW; Dalen JE; Fang MC; Go AS; Halperin JL; Lip GYH; Manning WJ
    Chest; 2008 Jun; 133(6 Suppl):546S-592S. PubMed ID: 18574273
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Vitamin K deficiency from long-term warfarin anticoagulation does not alter skeletal status in male rhesus monkeys.
    Binkley N; Krueger D; Engelke J; Suttie J
    J Bone Miner Res; 2007 May; 22(5):695-700. PubMed ID: 17295605
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation].
    Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
    G Ital Nefrol; 2017 Apr; 34(2):58-73. PubMed ID: 28682563
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Observations on possible effects of daily vitamin K replacement, especially upon warfarin therapy.
    Bern M
    JPEN J Parenter Enteral Nutr; 2004; 28(6):388-98. PubMed ID: 15568285
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Selection of Oral Anticoagulants in Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation.
    Deguchi I; Tanahashi N; Takao M
    J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2627-2631. PubMed ID: 29970321
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reduced bone density in patients on long-term warfarin.
    Rezaieyazdi Z; Falsoleiman H; Khajehdaluee M; Saghafi M; Mokhtari-Amirmajdi E
    Int J Rheum Dis; 2009 Jul; 12(2):130-5. PubMed ID: 20374330
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.
    Kalabalik J; Rattinger GB; Sullivan J; Slugocki M; Carbone A; Rivkin A
    Drugs; 2015 Jun; 75(9):979-98. PubMed ID: 25998374
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making.
    Noseworthy PA; Yao X; Gersh BJ; Hargraves I; Shah ND; Montori VM
    Int J Cardiol; 2017 Oct; 245():174-177. PubMed ID: 28733071
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Stroke prevention in atrial fibrillation: do we still need warfarin?
    Diener HC; Weber R; Lip GY; Hohnloser SH
    Curr Opin Neurol; 2012 Feb; 25(1):27-35. PubMed ID: 22143201
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anticoagulation Resumption After Stroke from Atrial Fibrillation.
    Mac Grory B; Flood S; Schrag M; Paciaroni M; Yaghi S
    Curr Atheroscler Rep; 2019 May; 21(8):29. PubMed ID: 31111239
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.
    Ezekowitz MD; Bridgers SL; James KE; Carliner NH; Colling CL; Gornick CC; Krause-Steinrauf H; Kurtzke JF; Nazarian SM; Radford MJ
    N Engl J Med; 1992 Nov; 327(20):1406-12. PubMed ID: 1406859
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation.
    Fanaroff AC; Ohman EM
    Annu Rev Med; 2019 Jan; 70():61-75. PubMed ID: 30477393
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to low-intensity warfarin therapy.
    Takarada K; Sato M; Goto M; Saito A; Ikeda Y; Fujita S; Fuse K; Takahashi M; Oguro T; Matsushita H; Kitazawa H; Okabe M; Abe H; Toba K; Yamashina A; Aizawa Y
    J Cardiol; 2014 Aug; 64(2):127-32. PubMed ID: 24440439
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.